Atlas Trials

A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Clinical trial NCT06276933 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06276933
Sponsor
Tongji University
Status
NOT_YET_RECRUITING
Phase
Phase 4
Study type
INTERVENTIONAL
Lung CancerCamrelizumab
Start date
2024-02-22
Primary completion
2025-11-22
Enrollment
104

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.